KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancerNaomi Nakayama, Kaoru Miyazaki|British Journal of Cancer|2008Cited by 114
NAC1 Regulates PCK2 Expression and Activates Truncated Gluconeogenesis for Growth Advantage in Ovarian Cancer CellsNaomi Nakayama, Satoru Kyo|International Journal of Molecular Sciences|2025Cited by 1